Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea

Reuters

2025/05/14

Agilent Technologies Inc. Enters Partnership with Ubix <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Advance Cancer Research in South Korea

**Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. $(A)$ has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation $(TPD.AU)$ and antibody-drug conjugate $(ADC)$ therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535026035"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535026035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535026035?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 06:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535026035","market":"nz","top_or_hot":-1,"title":"Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies Inc. Enters Partnership with Ubix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance Cancer Research in South Korea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. <a href=\"https://laohu8.com/S/A\">$(A)$</a> has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation <a href=\"https://laohu8.com/S/TPD.AU\">$(TPD.AU)$</a> and antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 06:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agilent Technologies Inc. Enters Partnership with Ubix <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to Advance Cancer Research in South Korea\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. <a href=\"https://laohu8.com/S/A\">$(A)$</a> has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation <a href=\"https://laohu8.com/S/TPD.AU\">$(TPD.AU)$</a> and antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2089279066.USD","symbol_name":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250513:nNDL360lQF:1","article_id":"2535026035","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535026035","pubTimestamp":1747175153,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc.  has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation  and antibody-drug conjugate  therapies. The partnership combines Ubix's Degraducer anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2089279066.USD":"ALLIANZ GLOBAL WATER \"AT\" (USD) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","LU1165135440.EUR":"BNP Paribas Aqua Classic Cap EUR","BK4567":"ESG概念","A":"安捷伦科技","LU2041044095.USD":"Blackrock Circular Economy A2 USD","BK4121":"生命科学工具和服务","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","BK4585":"ETF&股票定投概念","LU1721428933.USD":"法巴全球经典环境基金RH MD Dis","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","LU1543694498.USD":"法巴水资源基金RH MD Dis","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","LU2413666699.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"CRH\" (HKDHDG) INC","BK4588":"碎股","LU2229751404.USD":"ALLIANZ GLOBAL WATER \"AT3\" (USD) ACC"},"translate_title":"安捷伦科技公司与Ubix Therapeutics合作推进韩国癌症研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":0.9},"content_text":"Agilent Technologies Inc. Enters Partnership with Ubix Therapeutics to Advance Cancer Research in South Korea\n    \n\n        **Agilent Technologies Inc. Partners with Ubix Therapeutics to Accelerate Cancer Research in South Korea** SEOUL, South Korea - Agilent Technologies Inc. $(A)$ has announced a new partnership with Ubix Therapeutics to advance targeted cancer therapy research and development in South Korea. Over the next five years, this collaboration will focus on developing targeted protein degradation $(TPD.AU)$ and antibody-drug conjugate $(ADC)$ therapies. The partnership combines Ubix's Degraducer® anti-cancer drugs platform with Agilent's cutting-edge research and technology capabilities. This initiative aims to enhance precision oncology, with the global TPD market projected to reach USD 4.37 billion by 2034. This collaboration underscores Agilent's commitment to transformative cancer therapy and South Korea's biomedical advancement.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}